Literature DB >> 12620909

Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy.

Sarah L Blair1, Marcia Grant, David Z J Chu, Carey Cullinane, Grace Dean, Roderich E Schwarz, Lawrence Wagman.   

Abstract

BACKGROUND: Liver metastasis from colorectal cancer remains an oncological challenge. Hepatic chemotherapy has been used; however, rigorous quality of life (QOL) measurements are lacking. The aim of this study was to describe unique QOL issues to formulate a specific tool for this population.
METHODS: A purposive sample was identified of patients treated with intrahepatic chemotherapy. Consenting patients completed a demographic tool and the City of Hope QOL Scale/Cancer Patient survey. An in-depth interview on QOL concerns was conducted, taped, and transcribed verbatim. The data from the interviews were coded to identify recurrent themes.
RESULTS: Sixteen patients participated. Physical well-being was maintained. Significantly lower subscale scores were noted for psychological, social, and spiritual domains compared with nonpatient norms (City of Hope volunteers; n = 169). Patients found intrahepatic chemotherapy convenient but were unable to pursue vigorous activity, and their sleep habits changed. Psychologically, patients felt reassured to receive specific therapy to their liver.
CONCLUSIONS: Pilot evaluation of QOL in this population revealed changes in physical, psychological, social, and spiritual dimensions. Both disease- and treatment-specific concerns were identified, and the results provide evidence for items to include in a QOL questionnaire specific to this population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620909     DOI: 10.1245/aso.2003.03.060

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Spiritual well-being in long-term colorectal cancer survivors with ostomies.

Authors:  Joanna Bulkley; Carmit K McMullen; Mark C Hornbrook; Marcia Grant; Andrea Altschuler; Christopher S Wendel; Robert S Krouse
Journal:  Psychooncology       Date:  2013-06-07       Impact factor: 3.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.